Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Allergic Reactions02:06

Allergic Reactions

Overview
Antigens Involved in Adaptive Immunity01:26

Antigens Involved in Adaptive Immunity

An antigen is any substance the immune system identifies as foreign and potentially harmful to the body, prompting an immune response. Antigens have two functional properties: immunogenicity and reactivity. Immunogenicity is the ability of an antigen to stimulate a specific immune response. At the same time, reactivity describes the antigen's ability to react with the cells and antibodies produced in response to it.
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Cross-reactivity00:42

Cross-reactivity

Overview
Recombinant DNA01:09

Recombinant DNA

Overview
Recombinant DNA01:09

Recombinant DNA

Overview
Allergic Reactions: Anaphylaxis01:30

Allergic Reactions: Anaphylaxis

Anaphylaxis is a severe, life-threatening hypersensitivity reaction mediated by Immunoglobulin E (IgE) antibodies. When IgE binds to allergens, it triggers the release of mediators– histamine, leukotrienes, and prostaglandins from mast cells and basophils. These mediators cause vasodilation, edema, and inflammation, leading to various symptoms.The primary allergens causing anaphylaxis include food items (e.g., peanuts, shellfish), drugs (e.g., penicillin, asparaginase, corticotropin, heparin),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EAACI Guidelines on Environmental Science for Allergy and Asthma-Evidence-Based Recommendations for Prevention and Public Health Action to Mitigate the Impact of Pollen Exposure on Respiratory Allergy.

Allergy·2026
Same author

Polystyrene nanoplastics induce mitochondrial dysfunction and stress responses in human PBMCs.

Ecotoxicology and environmental safety·2026
Same author

Trace Elements in Allergy: Narrative Review.

Allergy·2026
Same author

Imbalance of type I and II interferon pathways is associated with pain perception in Sjogren's disease: a real-life study.

Frontiers in immunology·2026
Same author

Metabolic regulation of Th17/Treg balance.

Central-European journal of immunology·2026
Same author

Algorithms in Allergy: General Allergen Molecule-Based Algorithm for Allergen-Specific Immunotherapy.

Allergy·2026
Same journal

Economic and epidemiological burden of HPV-related diseases in the Czech Republic: A claims database analysis.

Human vaccines & immunotherapeutics·2026
Same journal

Shared clinical decision-making for vaccination: A view through the lens of mid-adult HPV vaccination.

Human vaccines & immunotherapeutics·2026
Same journal

Safety monitoring of bivalent, quadrivalent, and 9-valent human papillomavirus vaccination in Japan: The vaccine effectiveness, networking, and universal safety (VENUS) study.

Human vaccines & immunotherapeutics·2026
Same journal

Development of a theory-based provider-focused training to improve HPV vaccine recommendations for young adults.

Human vaccines & immunotherapeutics·2026
Same journal

Elranatamab: A novel B-cell maturation T-cell engager.

Human vaccines & immunotherapeutics·2026
Same journal

Mumps resurgence despite MMR: Limitations of current vaccines and the need for new strategies.

Human vaccines & immunotherapeutics·2026
See all related articles

Related Experiment Video

Updated: May 17, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Recombinant allergens: the present and the future.

Marek Jutel1, Katarzyna Solarewicz-Madejek, Sylwia Smolinska

  • 1Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland. marek.jutel@am.wroc.pl

Human Vaccines & Immunotherapeutics
|October 26, 2012
PubMed
Summary
This summary is machine-generated.

Recombinant allergen vaccines offer a safer and more effective treatment for allergies, including difficult-to-treat conditions like food allergies. These advanced vaccines significantly improve outcomes by modulating immune responses.

Keywords:
allergen-specific immunotherapyallergyhypoallergensrecombinant allergensvaccines

More Related Videos

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)

Published on: April 21, 2019

Related Experiment Videos

Last Updated: May 17, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
10:22

Humanized Mediator Release Assay as a Read-Out for Allergen Potency

Published on: June 29, 2021

Intralymphatic Immunotherapy and Vaccination in Mice
07:33

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)
07:10

Application of Biochip Microfluidic Technology to Detect Serum Allergen-specific Immunoglobulin E (sIgE)

Published on: April 21, 2019

Area of Science:

  • Immunology and Allergy Research
  • Vaccine Development

Background:

  • Allergen-specific immunotherapy (SIT) is the only causative treatment for allergic diseases.
  • Current SIT using allergen extracts has limitations in safety and efficacy, especially for conditions like food allergies and atopic dermatitis.

Purpose of the Study:

  • To introduce recombinant allergen-based vaccination strategies as an improved approach to SIT.
  • To enhance the safety and efficacy of treatments for allergic diseases.
  • To explore new vaccine options for allergies poorly responsive to traditional treatments.

Main Methods:

  • Development and clinical evaluation of recombinant allergen vaccines, including wild-type and hypoallergenic derivatives.
  • Assessment of vaccine efficacy and safety profiles in clinical studies.
  • Analysis of modulation of T and B cell responses to specific allergens.

Main Results:

  • Numerous successful clinical studies have been reported over the past decade.
  • Recombinant allergen vaccines demonstrate high efficacy and favorable safety profiles.
  • These vaccines induce strong modulation of both T and B cell responses.

Conclusions:

  • Recombinant allergen vaccines represent a significant advancement in treating allergic diseases.
  • They offer a promising alternative for allergies that do not respond well to conventional therapies.
  • The strategy shows potential for improved safety and enhanced immune response modulation.